Editorial

188Re, the New Workhorse of Radio Nuclide Therapy: Concepts to Clinical Use

Richard P. Baum1,* and Thomas W. Barber2

1 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) ENETS Center of Excellence
2 Department of Nuclear Medicine and PET, and Department of Medicine, Monash University, The Alfred Hospital, Melbourne, Australia

In 1925, the pioneering German chemists Ida Tackeand Walter Noddack announced the discovery of element 75 and named this new element rhenium in honor of the river Rhine (Latin Rhenus) [1]. The couple would later marry and continue their influential work as a team for the remainder of their professional careers. Remarkably, the pair also made valuable contributions to the discovery of technetium, which along with rhenium were the last two missing elements of the main periodic table at the time [1]. Both these elements belong to group 7 of the periodic table and thus share similar chemistry. Being suitable for therapeutic and diagnostic purposes respectively, 188Re and 99mTc therefore represent an ideal theranostic radionuclide pair. It now seems particularly fitting that the current partnering of these two radionuclides in a theranostic model stems from the discoveries of two partnering chemists almost a century ago.

188Re(T1/2=17 hours) has excellent physical properties as a therapeutic radionuclide. The high energy β emission (Eβ max=2.12 MeV) has a maximum range of 10.4 mm and the accompanying 155 keV energy gamma emission (15% abundance) facilitates imaging for biodistribution and dosimetry assessment [2]. In addition, the on-demand availability of 188Re from the tungsten-188(188W)/188Re generator can potentially allow daily clinical access in a cost effective manner per unit dose [3]. These attractive properties of 188Re have been utilized in several clinical applications over the last three decades including intra-arterial therapy of hepatocellular carcinoma, treatment of metastatic bone pain and radiosynoviorthesis [4-6].

In 2008 under the visionary guidance of Dr. Ajit Padhy, the International Atomic Energy Agency (IAEA) sponsored a multinational trial investigating the safety and efficacy of intra-arterial 188Re lipiodol in the treatment of inoperable hepatocellular carcinoma (HCC) [4]. This large phase II study involving 185 patients demonstrated that 188Re lipiodol therapy was feasible, safe and had promising efficacy with 78% of patients achieving either stable disease or objective response. This study was made possible only after decades of research from many dedicated scientists around the world including Dr. F.F (Russ) Knapp Jr from Oak Ridge National Laboratory, whose work made the 188W/188Re generator a reality and Dr. Jae Min Jeong, whose radiopharmaceutical expertise helped establish 188Re radiolabeling in kit formulation [7]. Following this landmark study, it was unfortunate that the momentum in propagating 188Re based therapies stalled, mostly due to the availability of other radionuclides such as 90Y and 177Lu for developing different products [3].

In this light, Dr. Ajit Padhy and the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) embarked on developing a188Re therapy program in 2013 at Kovai Medical Center and Hospital (KMCH) in Coimbatore, South India. Following treatment of the first patient with inoperable HCC at KMCH, and under the inspiring leadership of Dr Ajit Shinto, a new enthusiasm for this radionuclide therapy was born. After 1 year of experience with intra-arterial 188Re lipiodol therapy for inoperable HCC, their stunning data, demonstrating stable disease or objective response in 85% of patients, were presented at the 2014 World Federation of Nuclear Medicine and Biology Congress in Cancun, Mexico. At this moment, and as the president of WARMTH, I along with the other governing board members unanimously decided that WARMTH should actively support propagation of this therapeutic technique and a special task force for 188Re based therapies was created under the chairmanship of Dr. Ajit Shinto.
After 3 years of hard work we have come a long way and it is exciting to highlight some of our achievements. We now have a dedicated WARMTH $^{188}$W/$^{188}$Re generator available at a subsidized cost and on a regular basis, a major achievement given the previous lack of commercial interest. The first dedicated World Rhenium Congress(WRC) has been hosted by KMCH in 2015 under Dr. Ajit Shinto in collaboration with WARMTH. This landmark congress was a resounding success with participation from over 35 countries and almost 250 delegates in attendance. Workshops on $^{188}$Re dosimetry, $^{188}$W/$^{188}$Re generator radiochemistry, radiopharmaceutical applications and quality control have led to six new departments initiating $^{188}$Re based therapy programs, four from India and two from other Asian countries. It is has been most fulfilling to see the WARMTH $^{188}$Re taskforce plans translated into real world treatments within such a short period of time.

Continuing in this spirit, this special issue of the International Journal of Nuclear Medicine and Research aims to inspire new developments as well as build on established applications of $^{188}$Re based therapy in the nuclear medicine community. The broad range of topics presented in this issue and the possibility of integrating $^{188}$Re into our growing number of radiopharmaceutical therapeutic options is particularly encouraging for the future of the field. With the potential for $^{188}$Re based peptide receptor radionuclide therapy (PRRT) and prostate-specific membrane antigen radioligand therapy (PRLT) a new era in radionuclide therapy is within reach. Perhaps, as an ideal theranostic combination, the partnership of $^{188}$Re and $^{99m}$Tc is set for a revival!

REFERENCES

https://doi.org/10.3413/nuk2015050001


https://doi.org/10.2174/187447101205030228

https://doi.org/10.1053/j.semnuclmed.2007.10.006

https://doi.org/10.1200/JCO.2003.12.060

https://doi.org/10.1097/MNM.0b013e32833d6869

https://doi.org/10.1053/j.semnuclmed.2007.10.003

Received on 20-05-2017 Accepted on 29-05-2017 Published on 31-07-2017

http://dx.doi.org/10.15379/2408-9788.2017.01

© 2017 Baum and Barber; Licensee Cosmos Scholars Publishing House. This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.